Lung cancer is the most commonly diagnosed malignancy, which is reported to account for about 1.82 million new cases and 1.59 million mortalities globally in 2012.\(^1\) Non-small cell lung cancer (NSCLC) is one deadly type of lung cancer, which occurs in approximately 85\% to 90\% of all cases. Various treatment options have been available in recent years, such as minimally invasive surgical treatment, radiation therapy, systemic chemotherapy and targeted therapy, however, the treatment regimens mainly rely on the disease stage or performance status, and the long-term survival of patients with NSCLC is dismal. For example, only 13–36\% of patients with NSCLC survive five years after diagnosis.\(^2\,^3\) Moreover, lung cancer, with many variants, frequently metastasize to bone, brain, lung and liver, and drugs that target distant metastases often do not work in the adjuvant settings,\(^4\) or worse, wreak havoc on healthy cells and tissues,\(^5\,^6\) causing poor prognosis and high mortality.\(^7\,^8\) Thus, new therapies that overcome the current obstacles such as drug resistance, side effects, and poor specificity provide hope for the treatment of NSCLC in the future.

During the last two decades, with the development of nanotechnology, nanoparticles have gained growing interest as promising agents and have been applied for biomedical research\(^9\,\ldots\,12\) including drug manufacture, imaging, biological tagging, anticancer drugs, drug delivery, antibiotic development, gene transmission, tissue engineering, etc. Although more research is necessary, various nanoparticles play an important role in therapeutics and diagnostic agents, which has high specific surface area and easily penetrate the cell membranes and the biological barriers.

Silver nanoparticles (AgNPs) are emerging as one of the fastest growing nanotechnology-based product categories, and they have been successfully used for both in vivo and in vitro anticancer therapies because they are easy to make and stable.\(^13\,\ldots\,15\) It has been presented that AgNPs and their related products including surgical instruments and wound dressings show wide spectrum of biological activities and strong inhibitory effect on the growth, thus suggesting their widespread applications as nanomedicine.\(^16\,\ldots\,18\) Nevertheless, the molecular mechanism of cancer cell death caused by treatment of AgNPs seem to be still under investigation, although much research pointed out that, at the nano-scale, size is considered as one of the important criteria that governs the physicochemical properties of nanoparticles and ultimately their biological behaviour. In the present study, the effects of AgNPs with different sizes against A549 lung adenocarcinoma (a common type of NSCLC) cells was explored, and the data demonstrated that the smaller AgNPs (13 nm) were more toxic and significantly suppressed the migratory and invasive abilities of A549 cells, while no such changes were observed with larger nanoparticles. Furthermore, we found that 13 nm AgNPs inhibited the growth and invasion of lung cancer cells in vitro by inducing apoptosis via NF-κB signaling pathway, accompanied by the up-regulation of pro-apoptotic proteins and the down-regulation of anti-apoptotic proteins. These are promising observations and provide valuable information on the size-dependent anticancer activity of AgNPs for potential human applications against invasion of lung adenocarcinoma.

Experimentally, AgNPs with different sizes were successfully synthesized.\(^19\,\ldots\,22\) SEM images of AgNPs (Fig. 1a–c) revealed that the as-prepared AgNPs were well dispersed with uniform sizes. By counting the nanoparticles in the SEM images, the average particle sizes were calculated, which were 13.02, 45.21 and 92.18 nm (Fig. 1a–c, inset histograms), and termed to be 13, 45 and 92 nm in the following study. Moreover, as Fig. 1d showed, AgNPs with the size of 13, 45 and 92 nm have surface plasmon absorption at 388, 408 and 468 nm, respectively, which is...
The primary challenges of preparing nano-materials suitable in biological-medical area are to keep the nanoparticles away from aggregation and retain constant physicochemical properties in physiological conditions. It has been observed that there was no significant change in the absorption peak of AgNPs incubated with cell medium up to 72 h (Data not shown). MTT assay was then performed to assess the cytotoxicity of the AgNPs. Various concentrations of AgNPs (13, 45 and 92 nm) were incubated with A549 and L929 cells (mouse subcutaneous connective tissue and fat fibroblast cell, as the normal control) for up to 72 h, and the cell viabilities were measured. Cell viability of L929 cells was observed to be over 80% as compared to untreated cells at all the sizes and maximum concentration, and no obvious changes were observed at different time (Fig. S1†), suggested that AgNPs in the size range of 13–92 nm and the concentration range used in this work are largely non-toxic to normal cells. The anti-proliferation effect of AgNPs against A549 cells was evaluated at the same experiment condition, which showed higher cytotoxicity in dose-, time- and size-dependent manners and smaller AgNPs increased the toxicity against A549 cells, which is consisted with previous report.22 Based on those results, the relatively low concentrations of AgNPs (13 nm, 1.0 µg mL⁻¹; 45 nm, 3.0 µg mL⁻¹; 92 nm, 20 µg mL⁻¹) were provided for the further experiments (cell viability > 90% and 70% for L929 and A549 cells, respectively).

As known, metastasis is the main characteristic of cancer, during which the metastatic cells migrate from the primary tumour to a distant tissue, invade surrounding tissues for entering blood and lymphatic circulations, and ultimately grow into a macroscopic metastatic lesion.23–25 To evaluate the size effect of AgNPs on migration of A549 cells, a wound healing assay was employed. The results demonstrated that the cells treated with AgNPs of 13 and 45 nm migrated more slowly to close the scratched wounds compared with that of 92 nm AgNPs and untreated A549 group (Fig. 2).

Furthermore, a transwell invasion assay was then performed to investigate the effect of AgNPs on the invasive abilities of A549 cells. Fig. 3 showed that the ability of A549 cells to invade through the matrigel matrix was significantly decreased incubated with 13 nm AgNPs, while the invasion of A549 cells was inhibited to some extent when incubated with 45 nm AgNPs, and no such effect was observed in 92 nm AgNPs treated or A549-con group (Fig. 3). Taken together, these results suggested that 13 nm AgNPs could significantly inhibit the migratory and invasive abilities of A549 cells in vitro, and no similar effect was observed at the size of 92 nm.

To investigate the mechanism of the halted migratory and invasive abilities of A549 cells caused by AgNPs, subcellular localization of AgNPs was then performed under a dark-field microscope, and we could clearly observe the distribution of AgNPs in cytoplasm of A549 cells (Fig. S2†). In the control group, however, under the same condition, there was no significant number of particles except the obvious aggregated dots driving from the non-specific adsorption, indicated that AgNPs could successfully and efficiently entered the cells via endocytosis and accumulated in cytoplasm. Interestingly, more dark-field light scattering signal was obtained in the 13 nm AgNPs treated A549 cells due to the small size effect.

Reactive Oxygen Species (ROS) are the natural by-products of normal metabolism and play crucial roles in cell signalling and homeostasis, most of which are generated by oxidative phosphorylation (OXPHOS) in mitochondria. Increasing level of intracellular ROS induced by chemotherapeutic drugs may result in significant damage to cell morphology and lead to cell death.26 In order to determine the potential effect of AgNPs to ROS generation, dihydroethidium (DHE) staining was then involved (Fig. 4). DHE is a widely used probe, which shows very weak fluorescence and turns into significant enhanced fluorescent signal when oxidized by ROS or some other peroxides in cells. As shown in Fig. 4, AgNPs of different sizes showed distinct effect on intracellular ROS level. After exposure to 13 nm and 45 nm AgNPs, the cells showed strong red fluorescence (Fig. 4b and c), and the fluorescence of DHE was strongest.
in cells incubated with 13 nm AgNPs, whereas in the untreated control cells (Fig. 4a) and that treated by 92 nm AgNPs (Fig. 4d) quite poor fluorescence was observed, suggesting that 13 and 45 nm AgNPs-treatment induced oxidative stress. As more number of red fluorescent cells have been noted during treatment of the smaller AgNPs (13 and 45 nm), the size-dependent cytotoxicity might be caused due to elevated level of ROS in A549 cells treated by smaller AgNPs, which could penetrate cell membrane and located in the lysosome and mitochondria, and subsequently lead to cellular/DNA damages.

To further clarify the effect of size on lung cancer cell death, cell apoptosis studies were investigated in A549 cells treated by AgNPs, and the protein levels of apoptosis related protein-Bax, Bcl-2 and Bad were determined. As shown in Fig. 5, the content of Bad, which is anti-apoptotic, increased significantly after incubated with 13 nm AgNPs, while no obvious changes were obtained when the cells were treated with larger nanoparticles. Similarly, 13 nm AgNPs causes a reduction in the levels of the anti-apoptotic protein Bcl-2, while an associated increase in the level of pro-apoptotic protein Bax was observed (Fig. 5), leading to an increase in the ratio of Bax/Bcl-2.

Much experimental research has reported that the inhibition of nuclear factor (NF)-κB activation can lead to the inhibition of cell growth, invasion and apoptosis in various types of cancer cells. Following this line, the activity of NF-κB in A549 cells was further analysed to investigate the possible apoptotic mechanism, and the results revealed that 13 nm AgNPs was able to significantly upregulate the phosphorylation of NF-κB (p-NF-κB) in A549 cells (Fig. 5). These results suggest a potential apoptotic effect of 13 nm AgNPs against A549 cells via the NF-κB signalling pathway. Based on all of the above results, we speculate that, AgNPs, which are pointed out that have a sustained release of Ag⁺ in an environment with lower pH (such as cancer cells), may create free radicals and induce oxidative stress,
inhibit the migration and invasiveness of cells, and thus further lead to cell apoptosis (Fig. 6). Additionally, the biological activity of particles increases as the particle size decreases, since the smaller particles have larger surface area per unit mass and increased potential for biological interaction.\textsuperscript{14}

**Conclusions**

In conclusion, this study suggests that size of AgNPs plays a significant role in suppressing the migration and invasion of lung adenocarcinoma cells \textit{in vitro}, and this inhibitive effect is most pronounced treated with 13 nm AgNPs, while the effect starts decreasing with the size of 45 nm and completely vanishes for 92 nm AgNPs. Further experiment is performed to investigate the possible molecular mechanism, and the results reveal that 13 nm AgNPs are able to induce the generation of ROS and cell apoptosis by activating NF-\(k\)B, accompanied with an increase in the expression of NF-\(k\)B target proteins that are pro-apoptotic: Bad, Bax, and the decrease of anti-apoptotic protein: Bcl-2, suggesting that 13 nm AgNPs may be a potential therapeutic target for lung adenocarcinoma therapy. Although future studies are necessary on proving the anticancer efficacy of AgNPs using \textit{in vivo} models, the data in this work provides strong indication that AgNPs can be effective preventive agents against lung adenocarcinoma.

**Conflicts of interest**

There are no conflicts to declare.

**Acknowledgements**

This work was funded by National Natural Science Foundation of China (No. 81700237, 31571172 and 81870343); Fundamental Research Funds for the Central Universities (No. 2018CDXXXY0027 and 2018CDQYYX0042), and Chongqing Research Program of Basic Research and Frontier Technology grant (No. cstc2016jcyjA0407).

**Notes and references**

1 F. Islami, L. A. Torre and A. Jemal, \textit{Transl. Lung Cancer Res.}, 2015, 4, 327–338.

2 K. D. Miller, R. L. Siegel, C. C. Lin, A. B. Mariotto, J. L. Kramer, J. H. Rowland, K. D. Stein, R. Alteri and A. Jemal, \textit{Ca-Cancer J. Clin.}, 2016, 66, 271–289.

3 N. Katakami, H. Tada, T. Mitsudomi, S. Kudoh, H. Senba, K. Matsui, H. Saka, T. Kurata, Y. Nishimura and M. Fukuoka, \textit{Cancer}, 2012, 118, 6126–6135.

4 E. V. Cutsem, D. Lambrechts, H. Prener, R. K. Jain and P. Carmeliet, \textit{J. Clin. Oncol.}, 2011, 29, 1–4.

5 J. K. Horton and S. H. Wilson, \textit{Mol. Cancer Res.}, 2013, 11, 13–18.

6 J. K. Horton, J. F. Gleason, H. D. Klepin, S. Isom, D. B. Fried and A. M. Geiger, \textit{Cancer}, 2011, 117, 4033–4040.

7 M.-L. M. Coussa-Koniski, P. A. Maalouf, N. E. Raad and N. A. Bejjani, \textit{Respir. Med. Case. Rep.}, 2015, 15, 77–79.

8 K. Shedden, J. M. G. Taylor, S. A. Enkemann, M. S. Tsao, T. J. Yeatman, W. L. Gerald, S. Eschrich, I. Jurisica, S. E. Venkatraman, M. Meyerson, R. Kuick, K. K. Dobbin, T. Lively, J. W. Jacobson, D. G. Beer, T. J. Giordano, D. E. Misek, A. C. Chang, C. Q. Zhu, D. Strumf, S. Hanash, F. A. Shepherd, K. Ding, L. Seymour, K. Naoki, N. Pennell, B. Weir, R. Verhaak, C. Ladd-Acosta, T. Golub, M. Gruidl, J. Szoke, M. Zakowski, V. Rusch, M. Kris, A. Viale, N. Motoi, W. Travis and A. Sharma, \textit{Nat. Med.}, 2008, 14, 822–827.

9 R. R. Arvizo, S. Bhattacharyya, R. A. Kudgus, K. Giri, R. Bhattacharya and P. Mukherjee, \textit{Chem. Soc. Rev.}, 2012, 41, 2943–2970.

10 X. J. Lin, X. Q. Fan, S. J. Xiao, Y. He, W. J. Qi, P. P. Hu, Q. Y. Tan, X. Y. Tong and C. Z. Huang, \textit{New J. Chem.}, 2018, 42, 15311–15314.

11 R. S. Riley, C. H. June, R. Langer and M. J. Mitchell, \textit{Nat. Rev. Drug Discovery}, 2019, 18, 175–196.

12 A. Gupta, L. Holoidovsky, C. Thamaraiselvan, A. K. Thakur, S. P. Singh, M. M. Meijler and C. J. Arnusch, \textit{Chem. Commun.}, 2019, 55, 6890–6893.

13 F. A. Shiekh, \textit{Int. J. Nanomed.}, 2013, 8, 201–202.

14 S. Kokura, O. Handa, T. Takagi, T. Ishikawa, Y. Naito and T. Yoshikawa, \textit{Nanomedicine}, 2010, 6, 570–574.

15 X. Zhao, L. Zhou, M. S. R. Rajoka, L. Yan, C. Jiang, D. Shao, J. Zhu, J. Shi, Q. Huang, H. Yang and M. Jin, \textit{Crit. Rev. Biotechnol.}, 2018, 38, 817–835.

16 Y. He, Z. Du, S. Ma, Y. Liu, D. Li, H. Huang, S. Jiang, S. Cheng, W. Wu, K. Zhang and X. Zheng, \textit{Int. J. Nanomed.}, 2016, 11, 1879.

17 A. Dziedzic, R. Kubina, R. J. Buldak, M. Skonieczna and K. Cholewa, \textit{Molecules}, 2016, 21, 365.

18 K. Chaloupka, Y. Malam and A. M. Seifalian, \textit{Trends Biotechnol.}, 2010, 28, 580–588.

19 Y. Wang, S. J. Zhen, Y. Zhang, Y. F. Li and C. Z. Huang, \textit{J. Phys. Chem. C}, 2011, 115, 12815–12821.

20 J. Ling, Y. F. Li and C. Z. Huang, \textit{Anal. Chem.}, 2009, 81, 1707–1714.

21 D. Steinigeweg and S. Schlücker, \textit{Chem. Commun.}, 2012, 48, 8682–8684.

22 G. Oberdörster, A. Maynard, K. Donaldson, V. Castranova, J. Fitzpatrick, K. Ausman, J. Carter, B. Karn, W. Kreyling, D. Lai, S. Olin, N. Monteiro-Riviere, D. Warheit and H. Yang, \textit{Part. Fibre Toxicol.}, 2005, 2, 8.

23 P. S. Steeg, \textit{Nat. Med.}, 2006, 12, 895–904.

24 L. A. Mina and G. W. Sledge, \textit{Nat. Rev. Clin. Oncol.}, 2011, 8, 323–332.

25 Z. Aktary, M. Alaeef and M. Pasdar, \textit{Oncotarget}, 2017, 8, 32270–32291.

26 Y. Yang, R. M. Villani, H. Wang, M. J. Simpson, M. S. Roberts, M. Tang and X. Liang, \textit{J. Exp. Clin. Cancer Res.}, 2018, 37, 266.

27 L. Q. Chen, S. J. Xiao, L. Peng, T. Wu, J. Ling, Y. F. Li and C. Z. Huang, \textit{J. Phys. Chem. B}, 2010, 114, 3655–3659.

28 L. Q. Chen, S. J. Xiao, P. P. Hu, L. Peng, J. Ma, L. F. Luo, Y. F. Li and C. Z. Huang, \textit{Anal. Chem.}, 2012, 84, 3099–3110.
29 B. Zhu, Y. Li, Z. Lin, M. Zhao, T. Xu, C. Wang and N. Deng, *Nanoscale Res. Lett.*, 2016, **11**, 198.

30 K. S. Siddiqi, A. Husen and R. A. K. Rao, *J. Nanobiotechnol.*, 2018, **16**, 14.

31 X. Huang, Y. Teng, H. Yang and J. Ma, *Braz. J. Med. Biol. Res.*, 2016, **49**, e5717.

32 H. Chen, Y. Huang, J. Huang, L. Lin and G. Wei, *Oncol. Rep.*, 2017, **37**, 865–870.

33 J. Jiang, G. Geng, X. Yu, H. Liu, J. Gao, H. An, C. Cai, N. Li, D. Shen, X. Wu, L. Zheng, Y. Mi and S. Yang, *Oncotarget*, 2016, **7**, 87271–87283.

34 F. R. Cassee, H. Muijser, E. Duistermaat, J. J. Freijer, K. B. Geerse, J. C. Marijnissen and J. H. Arts, *Arch. Toxicol.*, 2002, **76**, 277–286.